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EDITORIALNew Tricks of Our Old Friend the Glucocorticoid Receptor
From Combating Ulcerative Colitis to Preventing Associated Colorectal Cancerlcerative colitis is the most common form of in-Uflammatory bowel disease (IBD) and a major risk
factor for the development of colorectal cancer.1 Synthetic
glucocorticoids are essential drugs in combatting inflam-
matory diseases and mediate their anti-inflammatory ac-
tions by binding the glucocorticoid receptor (GR). Despite
its clinical importance, prolonged glucocorticoid treatment
is hampered by the emergence of glucocorticoid resistance
and detrimental side effects.2 Therefore, it is crucial to
optimize glucocorticoid use in IBD, which requires an
improved understanding of the glucocorticoid action in IBD.
Because GR is ubiquitously expressed, glucocorticoids
can affect different cell types in the colon, including immune
cells and intestinal epithelial cells (IECs). Using a dextran
sulfate sodium (DSS)-induced colitis model, GR deletion in
myeloid cells was shown to inhibit the resolution (but not
the acute) phase of the disease, which was accompanied by
increased infiltration of macrophages and proinflammatory
cytokine expression in the colon.3 Yet, for ulcerative colitis
the role of GR in IECs has remained largely unresolved.
Earlier work showed that GR deletion in IECs coincided
with transient upregulation of proinflammatory chemokines
and cytokines in basal conditions,4 but an inflammatory or
tumorigenic context was not considered. In this issue of
Cellular and Molecular Gastroenterology and Hepatology, the
group of Reichardt took a more direct approach and used
both a DSS-induced colitis model and a colitis-associated
colorectal cancer model, in which the intestinal epithelial
GR was inducibly deleted (GRvillin mice), to investigate GR
action in IECs.5 These authors showed that DSS-induced
colitis was clearly exacerbated in GRvillin mice compared
with GRflox mice that still express wild-type GR. More spe-
cifically, GRvillin mice displayed decreased body weight,
worse clinical disease score, reduced colon length, and
increased serum interleukin-6 levels compared with GRflox
mice. This is further supported by their findings that
compared with GRflox mice, GRvillin mice showed both
aggravated DSS-induced tissue damage, and an even further
compromised epithelial barrier integrity.
Diving deeper into the mechanistic basis of the aggra-
vated colitis in GRvillin mice, Reichardt and colleagues
further studied the gene expression profile of IEC isolated
from colon.5 Several chemokines (Cxcl1, Cxcl5, Ccl5) that are
involved in the pathogenesis of colitis and attract immune
cells, such as neutrophils and monocytes, were only upre-
gulated in IEC of DSS-treated GRflox mice, suggesting that GR
triggers chemokine induction in IEC during inflammation, a
proinflammatory action that has been reported before.6 In
contrast, genes important for the control of the epithelial
barrier integrity (Tnfr2 and Mlck) or pathogen sensingCe(Tlr4) were overexpressed in IECs of GR-devoid GRvillin
mice, but not in functional GR-expressing GRflox mice, indi-
cating GR is required for the repression of these genes.
Together this suggests that endogenous glucocorticoids
safeguard epithelial permeability and block pattern recog-
nition receptor expression in IECs via binding to an IEC-
expressed GR, hereby limiting proinflammatory nuclear
factor-kB signaling.
Because chemokine expression was reduced in IEC of
DSS-treated GRvillin mice, a logical next step was to investi-
gate how this affected myeloid cell infiltration. In line with
the gene expression results, a reduced number of neutro-
phils, total and inflammatory macrophages, were found in
the lamina propria of DSS-treated GRvillin mice compared
with GRflox mice.5 This important finding indicates that GR
expression in IEC influences recruitment of myeloid cells in
the inflamed colon. To link this with the observed aggra-
vated colitis in GRvillin mice, a proinflammatory gene
expression analysis was performed in lamina propria cells.
Remarkably, chemokine and cytokine expression levels
were all strongly upregulated in lamina propria cells of
GRvillin mice compared with GRflox mice, indicative of
hyperactivated lamina propria cells.5
Because DSS-induced colitis was exacerbated in GRvillin
mice, the team of Reichardt further showed that this also
influenced tumorigenesis by using the carcinogen azoxy-
methane.5 In a DSS/azoxymethane model, both the number
and size of the developed tumors was strongly increased in
GRvillin mice compared with GRflox mice, although not linked
to changes in leukocyte infiltration.5 In an elegant experi-
ment where colitis and tumorigenesis were induced before
GR was deleted in IEC, the severity of colitis and the number
and size of the developed tumors showed to be comparable
in both genotypes.5 This clearly confirmed that the aggra-
vated colitis, and not the deleted GR in IECs, caused the
enhanced tumorigenesis. The role of GR in tumorigenesis
remains clinically relevant, not least because of the long-
term glucocorticoid use to relieve chemotherapy-
associated symptoms and perioperative to cancer
surgery,7 but also because of the ongoing debate concerning
the role of glucocorticoids in various solid cancers.8,9
This study greatly advances the understanding of GR
functioning in the colon and highlights that GR’s transcrip-
tional activation and repression mechanisms10 are involved
to control gene expression in IECs. Further questions remain
to be resolved. For instance, how would the inducible
expression of GR (dimerization) mutants steer these alter-
ations against a GRwt null background? Does GR expression
change over time in IECs of patient samples and does this GR
remain functional? Notwithstanding these open questions,llular and Molecular Gastroenterology and Hepatology 2021;-:-–-
2 Clarisse and Beck Cellular and Molecular Gastroenterology and Hepatology Vol. -, No. -Reichardt and colleagues clarified that GR action not only
keeps the inflammatory response in colitis under control, but
may also directly impact the progression toward colorectal
cancer. In extension, optimizing glucocorticoid treatment and
delivery strategies in patients may even decrease the risk of
developing colitis-associated colorectal cancer, highlighting
once more the importance of glucocorticoids and maintaining
a functional GR in the treatment of IBD.
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